5674.5000 -10.50 (-0.18%)
NSE Dec 01, 2025 10:35 AM
Volume: 8,081
 

5674.50
-0.18%
Motilal Oswal
With an established presence in the Domestic Formulation (DF) segment and exports, ALKEM is boosting its growth prospects in the bio-CDMO and med-tech segments. The overall investment in the bio-CDMO segment is expected to be ~INR14b.
Alkem Laboratories Ltd. is trading above all available SMAs
More from Alkem Laboratories Ltd.
Recommended